Drug Profile
Research programme: angiogenesis inhibitors - Athenagen
Alternative Names: ATG 001Latest Information Update: 23 Aug 2006
Price :
$50
*
At a glance
- Originator CoMentis
- Class
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 23 Aug 2006 Discontinued - Preclinical for Cancer in USA (PO)
- 21 Sep 2005 Preclinical trials in Cancer in USA (PO)